Allorion Therapeutics Funding: $105M Raised, Series B (2023)
Allorion Therapeutics is based in Cambridge. It has raised $105M in total funding. Latest round: Series B.
Allorion Therapeutics funding overview
Allorion Therapeutics is based in Cambridge. Allorion Therapeutics has raised $105M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in March 2023. The round record for Allorion Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include Qiming Venture Partners, IDG Capital, Longriver Investment Partners, TF Capital, INCE Capital, Firstred Capital and 2 others. 8 distinct backers are named across the disclosed rounds.
Allorion Therapeutics at a glance
Total raised
$105M
Latest round
Series B
Latest round date
March 2023
Headquarters
Cambridge
Notable investors
Qiming Venture Partners, IDG Capital, Longriver Investment Partners, TF Capital, INCE Capital, Firstred Capital, Elikon Venture, Octagon Capital
Frequently asked about Allorion Therapeutics funding
How much has Allorion Therapeutics raised?
Allorion Therapeutics has raised $105M in total disclosed funding across the rounds on record.
Who has invested in Allorion Therapeutics?
Qiming Venture Partners, IDG Capital, Longriver Investment Partners, TF Capital, INCE Capital, Firstred Capital are named among the investors backing Allorion Therapeutics.
What was the latest Allorion Therapeutics funding round?
The most recent disclosed round is a Series B, announced in March 2023.
Where is Allorion Therapeutics based?
Allorion Therapeutics is based in Cambridge.
When did Allorion Therapeutics last raise?
The last disclosed Allorion Therapeutics round closed in March 2023 at Series B.
We update the Allorion Therapeutics record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Cambridge and their backers are listed below.
